Commercial challenges of protein drug delivery

Bibliography

• Tractatus de corde item de motu et colore sanguinis et chyli in eum transitu (1669); facs. rept with English trans. In: R.T. Gunther, Early Science in Oxford. Oxford (1932) 9.
   Google Scholar
• BLUNDELL J: Successful case of transfusion. Lancet (1829) 1: 431–432.
   Google Scholar
• BLOOM AL: The evolution and future of haemophilia therapy. Transfus. Med. (1991) 1(1):5–12.
   PubMedGoogle Scholar
• •First blood transfusion to treat haemophilia.
   Google Scholar
• BAZIN H: The eradication of smallpox: Edward Jenner and the first and only eradication of a human infectious disease. Academic Press, San Diego (2000).
   Google Scholar
• BANTING FG, BEST CH: The internal secretion of the pancreas. J. Lab. Clin. Med. (1922) 8(5):1–16.
   Google Scholar
• ••The discovery of insulin.
   Google Scholar
• JENSEN HF: Insulin, its chemistry and physiology. Oxford University Press, New York (1938) 92–112.
   Google Scholar
• ••Early history of insulin research.
   Google Scholar
• LEWIS J: Insulin administration problem. Physiol. Rev. (1949) 29:75.
   PubMed Web of Science ®Google Scholar
• HAGEDOR HC, JENSEN BN, KRARUP BN, WODSTRUP K: Protamine insulinate. /AMA (1936) 106:177.
   Google Scholar
• SCOTT D, FISHER AJ: Prolongation of insulin action by protamine and zinc. J. Biol. Chem. Sc. Proc. (1936) 114:88.
   Google Scholar
• HALLAS-MOLLER K, JERSILD M, PETERSON K: Insulin preparations for single daily injection, clinical studies of new preparations with prolonged action. JAMA (1952) 150:1667.
   PubMed Web of Science ®Google Scholar
• MORROW JF, COHEN SN, CHANG AC et al.: Replication and transcription of eukaryotic DNA in Ewherichia coli. Proc. NatL Acad. Sci. USA (1974) 71: 1743-1747.
   Google Scholar
• ITAKURA K, HIROSE T, CREA R et al.: Expression in escherichia coli of a chemically synthesized gene for the hormone somatostatin. Science (1977) 9:198(4321):1056–1063.
   PubMed Web of Science ®Google Scholar
• ••First human protein expression in bacteria.
   Google Scholar
• The therapeutic proteins outlook to 2007: an analysis of leading products and late-stage pipeline developments. Reuters Business Insight, Aug (2003).
   Google Scholar
• LEICHTER SB: The business of insulin: a relationship between innovation and economics. Clin. Diabetes (2003) 21:40–42.
   Google Scholar
• Med. Ad. News, May (2004) 23(5):70–72.
   Google Scholar
• SHAH RB, AHSAN F, KHAN MA: Oral delivery of proteins: progress and prognostication. Crit. Rev. Ther. Drug Carrier Sys. (2002) 19:135–169.
   PubMed Web of Science ®Google Scholar
• •Oral protein delivery.
   Google Scholar
• VIDEX EC: I25mg, 200mg, 250mg and 400mg Gastro-resistant,Capsules Bristol-Myers Squibb Pharmaceuticals Ltc4 Hounslow, UK May (2004).
   Google Scholar
• JOSLIN EP, GRAY H, ROOT HF: Insulin in and home. J. Metab. Res. (1922) 2:651.
   Google Scholar
• ••Early attempts to deliver insulin orally.
   Google Scholar
• CLEMENT S, DANDONA P, GORDON STILL J, KOSUTIC G: Oral modified insulin (HIM2) in patients with Type 1 diabetes mellitus: results from a Phase I/II clinical trial. Metab. (2004) 53:54–58.
   PubMed Web of Science ®Google Scholar
• DDAVP Tablets Package Insert, Aventis Pharmaceuticals. Inc., Bridgewater, NJ 08807 USA Rev. November 2002.
   Google Scholar
• VILHARDT H, LUNDIN S, FALCH J: Plasma kinetics of DDAVP in man. Acta PharmacoL lbxicoL (1986) 58: 379–381.
   PubMedGoogle Scholar
• •Enhancer-assisted delivery of insulin.
   Google Scholar
• SACHDEVA A, GULATI R, GUPTA U,BAPNA JS: Comparative bioavailability of two brands of cyclosporinee. Indian J. Pharm. (1997) 29:135–137.
   Google Scholar
• HOLT DW, MUELLER EA, KOVARIK JM et al.: Sandimmune® Neoral® pharmacokinetics: impact of the new oral formulation. Transplant Proc. (1995) 27(1):1434–1447.
   PubMed Web of Science ®Google Scholar
• •Pharmacoldnetics of oral cydosporin.
   Google Scholar
• CASEZ JP, TSCHOPP P, SANDBERG TSCHOPP A, LIPPUNER K, ZINGG E, JAEGER P: Effects of nasal calcitonin on bone mineral density following parathyroidectomy in patients with primary hyperparathyroidism. Horm. Res. (2003) 59:263–269.
   PubMed Web of Science ®Google Scholar
• CRANNEY A, TUGWELL P, ZYTARUK N et al.: Osteoporosis methodology group and the osteoporosis research advisory group. Meta-analyses of therapies for postmenopausal osteoporosis. VI. Meta-analysis of calcitonin for the treatment of postmenopausal osteoporosis. Endocr. Rev. (2002) 23(4):540–551.
   PubMed Web of Science ®Google Scholar
• PONTIROLI AE, ALBERETTO M, CALDERARA A, PAJETTA E, POZZA G: Nasal administration of glucagon and human calcitonin to healthy subjects: a comparison of powders and spray solutions and of different enhancing agents. Eur. J. Clin. PharmacoL (1989) 37(4):427–430.
   PubMed Web of Science ®Google Scholar
• CHAPLIN MD: Bioavailability of nafarelin in healthy volunteers. Am. J. Obstet. GynecoL (1992) 166(2):762–765.
   Google Scholar
• FEBER J, COCHAT P, HADJ-AISSA A, DUBOURG L, WRIGHT C, POZET N: Renal concentrating capacity test by desmopressin in children: intranasal or intravenous route? Am. J. NephroL (1993) 13(2):129–131.
   PubMed Web of Science ®Google Scholar
• •Bioavailability of nasal DDAVP.
   Google Scholar
• LAURSEN T, GRANDJEAN B, JORGENSEN JO, CHRISTIANSEN JS: Bioavailability and bioactivity of three different doses of nasal growth hormone (GH) administered to GH-deficient patients: comparison with intravenous and subcutaneous administration. Eur. EndocrinoL (1996) 135(3):309–315.
   PubMed Web of Science ®Google Scholar
• VALENSI P, ZIRINIS P, NICOLAS P, PERRET G, SANDRE-BANON D, ATTALI JR: Effect of insulin concentration on bioavailability during nasal spray administration. PathoL Biol. Paris (1996) 44(4):235–240.
   PubMed Web of Science ®Google Scholar
• HILSTED J, MADSBAD S, HVIDBERG A et al.: Intranasal insulin therapy: the clinical realities. Diabetologia (1995) 38(6):680–684.
   PubMed Web of Science ®Google Scholar
• •Possibility of nasal insulin is unrealistic.
   Google Scholar
• GANSSLEN M: Uber Inhalation von Insulin. Klin. Wchnschr. (1925) 4:71.
   Google Scholar
• PATTON JS, BUKAR J, NAGARAJAN S: Inhaled insulin. Adv. Drug Del. Rev. (1999) 35:235–247.
   PubMed Web of Science ®Google Scholar
• SKYLER JS, CEFALU WT, KOURIDESLA, et al.: Efficacy of inhaled human insulin in Type 1 diabetes mellitus: a randomised proof-of-concept study. Lancet (2001) 357:331–335.
   PubMed Web of Science ®Google Scholar
• ••Effective dry powder pulmonary delivery of insulin to diabetic patients.
   Google Scholar
• OWENS DR, ZINMAN B, BOLLI G: Diabet. Med. (2003) 20:886–898.
   PubMed Web of Science ®Google Scholar
• BROWN LR, JARPE M, MCGEEHAN J, QIN Y, MOORE E, HOGELAND K: Resp. Drug Del. IX. (2004) 2:477–480.
   Google Scholar
• SELAM JL: Insuline inhalée: résultats cliniques chez le diabétique de Type 2. Diabetes Metab. (2001) 27:S28–S32.
   PubMedGoogle Scholar
• BITONTI AJ, DUMONT JA, LOW SC et al.: Pulmonary delivery of an erythropoietin Fc fusion protein in non-human primates through an immunoglobulin transport pathway. Proc. NatL Acad. Sci. USA (2004) 101:9763–9768.
   PubMed Web of Science ®Google Scholar
• CEFALU, WT: Concept, strategies, and feasibility of noninvasive insulin delivery. Diabetes Care (2004) 27(1):239–246.
   PubMed Web of Science ®Google Scholar
• BROWN L, MUNOZ C, SIEMER L, EDELMAN E, LANGER R: Controlled release of insulin from polymer matrices: control of diabetes in rats. Diabetes (1986) 35(6):692–696.
   PubMed Web of Science ®Google Scholar
• ••Sustained-release biological activity ofinsulin in vivo
   Google Scholar
• KNOBIL, E. The GnRH pulse generator.Am. J. Obstet. GynecoL (1990) 163:1721–1727.
   PubMed Web of Science ®Google Scholar
• R&D Directorate Report No.54. Goserelin or other gonadotrophin releasing hormone (GnR11) analogues in the treatment of advanced prostate cancer. NHS Executive South and West, Report to the Development and Evaluation Committee. (1996) 13.
   Google Scholar
• OKADA H: One- and three-month release injectable microspheres of the LH-RH superagonist leuprorelin acetate. Adv. Drug Del. Rev. (1997) 28(1):43–70.
   PubMed Web of Science ®Google Scholar
• SARTOR O, DINEEN MK, PEREZ-MARRENO R, CHU FM, CARRON GJ, TYLER RC: An eight-month clinical study of LA-2575 30.0 mg: a new 4-month, subcutaneous delivery system for leuprolide acetate in the treatment of prostate cancer. Urology. (2003) 62:319–323.
   PubMed Web of Science ®Google Scholar
• SCOTT T, BLIZZARD C, BROWN L, RASHBA-STEP J, WAGNER L, RISKE F: Extended Release ProMaxirm LH-RH Analog Microspheres. Proceedings of the International Symposium on the Controlled Release of Bioactive Materials (1999) 26.
   Google Scholar
• LANCRANJAN I, BRUNS C, GRASS P, JAQUET J et al.: Sandostatin LARO: pharmacokinetics, pharmacodynamics, efficacy and tolerability in acromeglic patients. Metabolism (1995) 44:18–26.
   Web of Science ®Google Scholar
• SCARPIGNATO C, PELOSINI I, S: Somatostatin analogs for cancer treatment and diagnosis: an overview. Chemotherapy (2001) 47(2):1–29.
   PubMedGoogle Scholar
• WARNER B, WORGUL TJ, DRAGO J et al.: Effect of very high dose D-leucine6-gonadotropin-releasing hormone proethylamide on the hypothalamic-pituitary testicular axis in patients with prostatic cancer. J. Clin. Invest. (1983) 71(6):1842–1853.
   PubMed Web of Science ®Google Scholar
• DONG HN, YU SY, SNG DL et al.: Monitoring of peptide acylation inside degrading PLGA microspheres by capillary electrophoresis and MALDI-TOF mass spectrometry. J. Contr. Rel. (2003) 92(3):291–299.
   PubMed Web of Science ®Google Scholar
• JOHNSON OL, CLELAND JL, LEE HJ et al.: A month-long effect from a single injection of microencapsulated human growth hormone. Nat. Med. (1996) 7:795–799.
   Google Scholar
• BERKLAND C, KING M, COX A: Precisecontrol of PLG microsphere size provides enhanced control of drug release rates. J. Contr. Rel. (2002) 82:137–147.
   PubMed Web of Science ®Google Scholar
• Nutropin Depot G) Isomatropin(rDNAorigin)forinjectablesuspensi oril and diluent for nutropin depot package insert. Genentech, Inc. April (2002).
   Google Scholar
• KOZLOWSKI A. HARRIS JM: Improvements in protein Pegylation: pegylated interferons for treatment of hepatitis C. J. Contr. Rel. (2001) 72:217–224.
   PubMed Web of Science ®Google Scholar
• VERONESE FM: Peptide and protein Pegylation: a review of problems and solutions. Biomaterials (2001) 22(5):405–417.
   PubMed Web of Science ®Google Scholar
• •Increase in half-life of pegylated SOD.
   Google Scholar
• HEATHCOTE EJ, SHIFFMAN ML, COOKSLEY WG et al.: Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. New Engl. J. Med. (2000) 343:1673–1680.
   PubMed Web of Science ®Google Scholar
• •Single weekly injection of pegylated interferon is an effective as three-times-weekly unmodified interferon.
   Google Scholar
• OVERBAY DK, MANLEY HJ: Darbepoetin-alpha: a review of the literature. Pharmacotherapy (2002) 22(7): 889–897.
   PubMed Web of Science ®Google Scholar
• BROWN LR: Glucose-mediated insulin delivery from implantable polymers. In: Polymeric biomaterials. Dumitriu S (Ed.) Marcel Dekker, Inc, New York (2002) 1101–1115.
   Google Scholar
• •Polymeric insulin delivery.
   Google Scholar
• DEFELIPPIS MR, BAKAYSA M, BELL A et al.: Preparation and characterization of cocrystalline suspension of [LysB28,ProB29]-human insulin analogue. Pharm. Sci. (1998) 87: 170–176.
   Google Scholar
• •Amino acid substitution to form a rapid-acting insulin.
   Google Scholar
• HOME PD, BARRIOCANAL L, LINDHOLM A: Comparative pharmacokinetics and pharmacodynamics of the novel rapid acting insulin analogue, insulin aspart, in healthy volunteers. Eur. Clin. Pharmacol (1999) 55:199–203.
   Web of Science ®Google Scholar
• •Amino acid substitution to form a rapid-acting insulin.
   Google Scholar
• GILLIES PS, FIGGITT DP, LAMB HM: Insulin glargine. Drugs. (2000) 59:253–260.
   PubMed Web of Science ®Google Scholar
• •Twenty-four hour basal insulin concentrations with new insulin analogue.
   Google Scholar
• LUZIO SD, BECK P, OWENS DR: Horm. Metab. Res. (2003) 35(7):434–438.
   PubMed Web of Science ®Google Scholar
• •Insulin glargine pharmacokinetics.
   Google Scholar
• WOOD A: New methods of treating neuralgia by the direct of opiates to the painful points. Edinburgh Med. Surg. (1855) 16:265–281.
   Google Scholar
• HOWARD-JONES N: The origins of hypodermic medication. Sci. Am. (1971) 224:96–102.
   PubMed Web of Science ®Google Scholar
• LEE DM: How painful is intensive insulintherapy? Z. Gesamte Inn. Med. (1992) 47:266–269.
   PubMedGoogle Scholar
• SILVERSTEIN JH, MURRAY FT, MALASANOS T, MYERS S, JOHNSON SB, GROSSMAN M: Clinical testing results and high patient satisfaction with a new needle-free device for growth hormone in young children. Endocrine (2001) 15:15–17.
   PubMed Web of Science ®Google Scholar
• ROY N, AGARWAL S: Therapeutic proteinproduction -an overview. Business Briefing: Future Drug Discovery (2003) 79–82.
   Google Scholar
• PRESENT DH, RUTGEERTS P, TARGAN S et al.: Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J. Med. (1999) 340(18):1398–1405.
   PubMed Web of Science ®Google Scholar
• VOSE JM, LINK BK, GROSSBARD ML,, et al.: Phase II Study of Rituximab in Combination With CHOP Chemotherapy in Patients With Previously Untreated, Aggressive Non-Hodgkin's Lymphoma. J. Clin. Oncol. (2001) 15:389–397.
   Google Scholar
• PRESTA LG, CHEN H, O'CONNOR SJ et al.: Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. (1997) 57:4593–4599.
   PubMed Web of Science ®Google Scholar